Personalized contraception Adyn offers a unique Birth Control Test that uses genetic risk and hormone profiles to tailor contraception choices, presenting a direct opportunity to upgrade and expand into personalized medicine and reproductive health services for providers and clinics.

Clinical research potential By enabling anonymous participation in research through The Birth Control Test, adyn can partner with academic institutions, hospitals, and biotech firms to gather real-world data, opening doors for strategic collaborations and data-driven study opportunities.

Early-stage traction With a small team and modest revenue, adyn presents a scalable entry point for partnerships with larger healthcare platforms, fertility clinics, and payer networks looking to reduce adverse side effects and improve user satisfaction.

Tech-enabled onboarding The stated tech stack (Google Ads, Fullstory, Looker, AWS, etc.) indicates readiness for data-driven marketing, onboarding, and analytics partnerships; leverage this to propose joint go-to-market or co-marketing arrangements with health tech vendors.

Funding and growth levers Current funding and revenue levels suggest a need for strategic investors and customers; target venture networks, accelerators, or healthcare giants seeking to diversify in women’s health and personalized medicine.